Home/Pipeline/Ausel Cancer Test

Ausel Cancer Test

Multi-Cancer Early Detection

Pre-clinicalActive

Key Facts

Indication

Multi-Cancer Early Detection

Phase

Pre-clinical

Status

Active

Company

Ausel Cancer Innovation

About Ausel Cancer Innovation

Ausel Cancer Innovation is a private, pre-revenue diagnostics company founded in 2020, developing a novel multi-cancer early detection (MCED) test. The company's mission is to enable accurate and easy early detection of cancer, which could significantly improve patient outcomes through earlier intervention. Operating from Milan, Italy, Ausel appears to be in the pre-clinical or early development stage, building its technology platform. The competitive landscape is intense, with several large players advancing in the MCED space, posing both a validation of the market and a significant commercialization challenge.

View full company profile

Therapeutic Areas

Oncology

Other Multi-Cancer Early Detection Drugs

Drug	Company	Phase	Status
ALMANAC Study	Guardant Health	Research	Active
GAGome for MCED	Elypta	Clinical Validation	Active
Rivela MCED Test	EXOSOMICS	Pre-clinical	Active
CancerGuard™	Exact Sciences	Pivotal Studies	Active
PATHFINDER 2	GRAIL	Interventional Study	Active
REACH/Galleri-Medicare Study	GRAIL	Prospective Cohort Study	Active
REFLECTION Study	GRAIL	Observational Study	Active
SUMMIT Study	GRAIL	Observational Cohort Study	Active
PATHFINDER Study	GRAIL	Interventional Study	Completed
MCED Test	Mainz Biomed	Research Collaboration	Active